Alvotech Financial Statements
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alvotech revenue and earnings
In fiscal 2025, Alvotech generated $586.3 million in revenue, up 19.7% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $27.9 million, for a net margin of 4.8% versus a median of -276.0% in the prior 5 years. Gross margin was 59.8% (down from 62.2%) and operating margin 13.3%.
Diluted earnings per share came in at $0.10. Over the last 5 fiscal years, ALVO's revenue has grown at a 54.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Alvotech income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 586.32M | 489.68M | 91.43M | 83.03M | 36.77M | 66.62M |
| Revenue growth (YoY) | +19.74% | +435.56% | +10.12% | +125.79% | -44.80% | — |
| Cost of Revenue | 235.56M | 185.31M | 160.86M | 64.09M | 0 | — |
| Gross Profit | 350.76M | 304.37M | -69.42M | 18.93M | 36.77M | — |
| Operating Expenses | 272.56M | 234.73M | 285.44M | 365.38M | 272.23M | — |
| Research & Development | 184.19M | 171.31M | 210.83M | 180.62M | 191.01M | 148.07M |
| Operating Income | 78.21M | 69.64M | -354.86M | -346.44M | -235.46M | -137.54M |
| Interest Expense | 149.19M | 303.17M | 267.16M | 188.42M | 117.36M | 161.55M |
| Other Income (Expense) | 58.14M | -287.21M | -296.19M | -205.21M | 86.26M | -154.23M |
| Pretax Income | 136.35M | -217.56M | -651.05M | -551.65M | -149.20M | -291.77M |
| Income Tax | 108.43M | 14.30M | -99.32M | -38.07M | -47.69M | -121.73M |
| Net Income | 27.92M | -231.86M | -551.73M | -513.58M | -101.50M | -170.04M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 |
| EPS (Diluted) | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 |
| Shares Outstanding (Basic) | 289.73M | 267.92M | 227.26M | 197.72M | 110.67M | 93.65M |
| Shares Outstanding (Diluted) | 291.34M | 267.92M | 227.26M | 197.72M | 110.67M | 93.65M |
| EBITDA | 116.06M | 100.94M | -330.65M | -326.03M | -217.26M | -121.12M |
| Gross Margin | 59.82% | 62.16% | -75.93% | 22.80% | 100.00% | — |
| Operating Margin | 13.34% | 14.22% | -388.11% | -417.25% | -640.31% | -206.46% |
| Net Margin | 4.76% | -47.35% | -603.42% | -618.55% | -276.04% | -255.26% |
This table shows 6 annual periods of Alvotech's income statement, from FY 2025 back to FY 2020, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ALVO's reporting calendar. What is a income statement?